Financial Constraints to Molecular Biomarker Testing

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.

Related Videos

January 20, 2016

Which Part of Stem Cells Should Be Treated?

Dr Wainberg and Dr Gerson discuss the ongoing debate about whether clinicians should treat the surface or the internal structure of cancer stem cells.

August 29, 2018

How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer

Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.